Literature DB >> 33849512

Current antibiotic resistance patterns of rare uropathogens: survey from Central European Urology Department 2011-2019.

Jan Hrbacek1, Pavel Cermak2, Roman Zachoval3.   

Abstract

BACKGROUND: While the resistance rates of commonly detected uropathogens are well described, those of less frequent Gram-negative uropathogenic bacteria have seldom been reported. The aim of this study was to examine the resistance rates of less frequent uropathogenic Gram-negatives in a population of patients treated in a Department of Urology of a tertiary referral centre in Central Europe over a period of 9 years.
METHODS: Data on all positive urine samples from urological in- and out-patients were extracted form the Department of Clinical Microbiology database from 2011 to 2019. Numbers of susceptible and resistant isolates per year were calculated for these uropathogens: Acinetobacter spp. (n = 74), Citrobacter spp. (n = 60), Enterobacter spp. (n = 250), Morganella morganii (n = 194), Providencia spp. (n = 53), Serratia spp. (n = 82) and Stenotrophomonas maltophilia (n = 27). Antimicrobial agents selected for the survey included: ampicillin, amoxicillin/clavulanic acid, piperacillin/tazobactam; cefuroxime, cefotaxime, ceftazidime and cefepime; ciprofloxacin and ofloxacin; gentamicin and amikacin; ertapenem, meropenem and imipenem; trimethoprim-sulfamethoxazole (co-trimoxazole), nitrofurantoin and colistin.
RESULTS: Penicillin derivatives have generally poor effect except piperacillin/tazobactam. Cefuroxime is not efficient unlike cefotaxime (except against Acinetobacter spp. and S. maltophilia). Susceptibility to fluoroquinolones is limited. Amikacin is somewhat more efficient than gentamicine but susceptibilities for both safely exceed 80%. Nitrofurantoin shows virtually no efficiency. Cotrimoxazole acts well against Citrobacter spp., Serratia spp. and it is the treatment of choice for S. maltophilia UTIs. Among carbapenems, ertapenem was less efficient than meropenem and imipenem except for S. maltophilia whose isolates were mostly not suceptible to any carbapenems.
CONCLUSIONS: Uropathogenic microorganisms covered in this report are noteworthy for their frequently multi-drug resistant phenotypes. Knowledge of resistance patterns helps clinicians choose the right empirical antibiotic treatment when the taxonomical assignment of the isolate is known but sensitivity results are pending.

Entities:  

Keywords:  Acinetobacter; Anti-infective agents; Bacterial; Citrobacter; Drug resistance; Enterobacter; Morganella; Providencia; Serratia; Stenotrophomonas; Urinary; Urinary tract infections

Year:  2021        PMID: 33849512     DOI: 10.1186/s12894-021-00821-8

Source DB:  PubMed          Journal:  BMC Urol        ISSN: 1471-2490            Impact factor:   2.264


  4 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

Review 2.  Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.

Authors:  Joshua T Thaden; Jason M Pogue; Keith S Kaye
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

Review 3.  Trends in Antibiotic Resistance in Urologic Practice.

Authors:  Hala Kandil; Emma Cramp; Tejal Vaghela
Journal:  Eur Urol Focus       Date:  2016-10-05

4.  Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe.

Authors:  Stéphanie Guyomard-Rabenirina; Joyce Malespine; Célia Ducat; Syndia Sadikalay; Mélanie Falord; Dorothée Harrois; Vincent Richard; Charles Dozois; Sébastien Breurec; Antoine Talarmin
Journal:  BMC Microbiol       Date:  2016-06-24       Impact factor: 3.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.